Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $76.30 USD
Change Today -0.56 / -0.73%
Volume 297.8K
CRL On Other Exchanges
As of 8:04 PM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

charles river laboratories (CRL) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/20/15 - $84.69
52 Week Low
08/5/14 - $52.39
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

charles river laboratories (CRL) Related Bloomberg News

View More Bloomberg News

charles river laboratories (CRL) Related Businessweek News

No Related Businessweek News Found

charles river laboratories (CRL) Details

Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery and preclinical development services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily genetically and microbiologically defined purpose-bred rats and mice for use by researchers. This segment also offers a range of services to assist its clients in supporting the use of research models in drug discovery and development comprising genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for identification of a druggable target within a cell through delivery of clinical drug candidates; and safety assessment services, which comprise bioanalysis, pharmacokinetics, drug metabolism, toxicology, and pathology services. The Manufacturing segment provides non-animal or in vitro methods for lot release testing of medical devices and injectable drugs for endotoxin contamination. This segment also offers specialized testing of biologics and devices that are outsourced by pharmaceutical and biotechnology companies; and specific pathogen free fertile chicken eggs and chickens for the manufacture of live viruses. The company serves pharmaceutical and biotechnology companies, contract research organizations, agricultural and chemical companies, life science and veterinary medicine companies, contract manufacturing organizations, medical device companies, diagnostic and other commercial entities, hospitals, academic institutions, and government agencies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

7,900 Employees
Last Reported Date: 02/17/15
Founded in 1947

charles river laboratories (CRL) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $1.1M
Chief Financial Officer and Corporate Executi...
Total Annual Compensation: $530.3K
Corporate Executive Vice President and Presid...
Total Annual Compensation: $524.9K
Chief Scientific officer and Corporate Execut...
Total Annual Compensation: $518.1K
Chief Administrative Officer, General Counsel...
Total Annual Compensation: $587.5K
Compensation as of Fiscal Year 2014.

charles river laboratories (CRL) Key Developments

Charles River Laboratories Seeks Acquisitions

Charles River Laboratories International, Inc. (NYSE:CRL) announced that the company is very interested in continuing to grow, both organically and through mergers and acquisitions.

Celsis International Ltd., Charles River Laboratories International, Inc. - M&A Call

To discuss the company entered into a definitive agreement to acquire Celsis International Ltd

Charles River Laboratories International Seeks Acquisitions

Charles River Laboratories International, Inc. (NYSE:CRL) is seeking acquisitions. Jim Foster, Charles River's Chairman, President & Chief Executive Officer, said "We are going to look at acquisition opportunities in our highest growth, highest margin businesses that have the best long term potential, of which EMD is number one. So this has been consistently our best business, and by best, I mean consistently highest growing and very profitable."


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CRL:US $76.30 USD -0.56

CRL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bioanalytical Systems Inc $1.37 USD -0.05
Ergomed PLC 180.00 GBp 0.00
PAREXEL International Corp $68.73 USD -0.75
PRA Health Sciences Inc $42.78 USD +0.56
WuXi PharmaTech Cayman Inc $41.75 USD +0.02
View Industry Companies

Industry Analysis


Industry Average

Valuation CRL Industry Range
Price/Earnings 26.0x
Price/Sales 2.7x
Price/Book 5.1x
Price/Cash Flow 21.8x
TEV/Sales 2.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHARLES RIVER LABORATORIES, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at